March 12, 2024   USA podcast interview with CEO Ulf Hannelius

In this podcast episode, Diabetes Daily Grind founder Amber Clour chats with Ulf Hannelius, CEO of Diamyd Medical, about their groundbreaking investigational immunotherapy that aims to safely and specifically slow down or halt the autoimmune destruction of insulin producing cells.

Listen to the podcast here

Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research